Hospira (HSP) is a provider of specialty injectable pharmaceuticals and infusion technologies. Despite its regulatory troubles of the past five years, Hospira is strategically one of the best positioned companies in the biopharma industry. The company's unique generic injectable capacity and its ability to develop biosimilars, both play into healthcare cost reductions around the world. We believe we are near the tail end of Hospira's regulatory woes and the stock will have a multi-year run, doubling in the next two years. The company is likely to see additional gains through several product launches over the next five years creating strong cash flows, providing opportunities to augment its pipeline and make investments in overseas manufacturing to boost margins...
Hospira: Regulatory Woes, Pipeline, And Potential Takeout Offer Asymmetric Multi-Bagger Opportunity
Sep 30 2013, 10:45 | about: HSP
BOOKMARKED / READ LATER
Added to your bookmarks on the Seeking Alpha homepage
Editor's notes: HSP's shares have been held back by abnormal earnings and regulatory issues, but biotech expert Buddy Lyons says a turn is coming. Triple-digit upside as the headwinds fade.